E-viri
Recenzirano
-
Alexandrou, Michaella; Mutlu, Deniz; Rempakos, Athanasios; Al Ogaili, Ahmed; Choi, James W; Poommipanit, Paul; Alaswad, Khaldoon; Basir, Mir Babar; Davies, Rhian; Jaffer, Farouc A; Dattilo, Phil; Azzalini, Lorenzo; Aygul, Nazif; Reddy, Niranjan; Jefferson, Brian K; Gorgulu, Sevket; Khatri, Jaikirshan J; Young, Laura D; Krestyaninov, Oleg; Khelimskii, Dmitrii; Frizzell, Jarrod; Elbarouni, Basem; Rangan, Bavana V; Mastrodemos, Olga C; Burke, M Nicholas; Sandoval, Yader; Brilakis, Emmanouil S
The Journal of invasive cardiology, 2024-Apr-30, 2024-4-30, 20240430Journal Article
Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).
